Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fibrosarcoma
Scientists at Shandong University publish new data on fibrosarcoma
July 29th, 2008
According to recent research published in the journal Cancer Gene Therapy, "Therapy targeting hypoxia-inducible factor-1 (HIF-1) to reverse the hypoxia-related drug resistance has received much interest. Despite a close interaction between HIF-1 and p53 and that p53 mutation is seen in > 50% of tumors, whether HIF-1 silencing by targeted therapy depends on tumor p53 status remains unknown." "Two isogenic fibrosarcoma cells HT1080 (wild-type p53) and HT1080-6TG (mutant p53) were transduced with HIF-1 alpha-specific RNAi lentiviral vectors and selected with blasticidin. Real-time PCR and western blot analysis of HIF-1 alpha mRNA and protein respectively...
Source: Cancer Weekly (2008-07-29)
|
